#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	13608	16S	1529	1529	99.93	16S.l15.c17.ctg.2	2203	736.7	0	.	n	.	0	C1450T	SNP	1450	1450	C	1717	1717	T	884	T,G,C	878,3,3	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	13608	16S	1529	1529	99.93	16S.l15.c17.ctg.2	2203	736.7	1	SNP	n	C1184T	0	.	.	1184	1184	C	1451	1451	C	815	C	815	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	13608	16S	1529	1529	99.93	16S.l15.c17.ctg.2	2203	736.7	0	HET	.	.	.	A69G	.	69	69	A	336	336	A	847	A,G	530,316	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23218	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4021	720.6	0	.	n	.	0	G1337A	SNP	1337	1337	G	1920	1920	A	946	A,T,G,C	943,1,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23218	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4021	720.6	0	.	n	.	0	T1971C	SNP	1971	1971	T	2554	2554	C	829	C,T	828,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23218	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4021	720.6	1	SNP	n	A2045G	0	.	.	2045	2045	A	2628	2628	A	774	A,T	773,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23218	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4021	720.6	1	SNP	n	C2597T	0	.	.	2597	2597	C	3180	3180	C	799	C,A	798,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_Z_01426c	folP.WHO_Z_01426c	1	1	539	2168	folP	852	852	99.88	folP.l15.c17.ctg.1	2216	122.1	0	.	p	.	0	E151K	NONSYN	451	453	GAA	1169	1171	AAA	226;225;228	A,G;A;A	224,2;225;228	.	.
folP.WHO_Z_01426c	folP.WHO_Z_01426c	1	1	539	2168	folP	852	852	99.88	folP.l15.c17.ctg.1	2216	122.1	1	SNP	p	R228S	1	.	.	682	684	AGC	1400	1402	AGC	226;229;229	A;G;C	226;229;229	folP.WHO_Z_01426c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4606	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3937	146.2	1	SNP	p	S91F	0	.	.	271	273	TCC	878	880	TCC	196;195;195	T;C,T;C	196;194,1;195	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4606	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3937	146.2	1	SNP	p	D95G	0	.	.	283	285	GAC	890	892	GAC	194;196;197	G;A;C	194;196;197	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4606	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3937	146.2	1	SNP	p	D95N	0	.	.	283	285	GAC	890	892	GAC	194;196;197	G;A;C	194;196;197	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	27	1864	mtrR	633	633	100.0	mtrR.l6.c30.ctg.1	1966	118.4	1	SNP	p	G45D	0	.	.	133	135	GGC	763	765	GGC	191;191;193	G;G;C	191;191;193	mtrR.WHO_X_01389:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	1048	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1506	86.9	0	.	n	.	0	A197.	DEL	197	197	A	873	873	A	195	A	194	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4426	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3546	155.9	1	SNP	p	D86N	0	.	.	256	258	GAC	854	856	GAC	195;196;198	G;A,T,C;C	195;194,1,1;198	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4426	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3546	155.9	1	SNP	p	S87R	0	.	.	259	261	AGT	857	859	AGT	196;196;198	A;G;T	196;196;198	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4426	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3546	155.9	1	SNP	p	S87W	0	.	.	259	261	AGT	857	859	AGT	196;196;198	A;G;T	196;196;198	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4426	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3546	155.9	1	SNP	p	S87I	0	.	.	259	261	AGT	857	859	AGT	196;196;198	A;G;T	196;196;198	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4426	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3546	155.9	1	SNP	p	S88P	0	.	.	262	264	TCC	860	862	TCC	198;202;204	T;C;C	198;202;204	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	3936	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3082	159.1	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1686	1688	GGC	200;199;196	G;G,A;C	200;198,1;196	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.9.001	penA.9.001	1	1	27	3882	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2953	164.1	1	SNP	p	A311V	0	.	.	931	933	GCA	1537	1539	GCA	225;226;226	G,C,T;C;A	222,2,1;226;226	penA.9.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3882	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2953	164.1	1	SNP	p	I312M	0	.	.	934	936	ATC	1540	1542	ATC	229;229;228	A;T;C,G	229;229;227,1	penA.9.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3882	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2953	164.1	1	SNP	p	V316T	0	.	.	946	948	GTG	1552	1554	GTG	233;238;239	G;T,C;G	233;237,1;239	penA.9.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3882	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2953	164.1	1	SNP	p	V316P	0	.	.	946	948	GTG	1552	1554	GTG	233;238;239	G;T,C;G	233;237,1;239	penA.9.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3882	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2953	164.1	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2056	2058	ACC	205;209;211	A,T,G;C,T;C	203,1,1;208,1;211	penA.9.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3882	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2953	164.1	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2110	2112	GCG	201;202;202	G;C,A;G	201;201,1;202	penA.9.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3882	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2953	164.1	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2110	2112	GCG	201;202;202	G;C,A;G	201;201,1;202	penA.9.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3882	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2953	164.1	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2233	2235	GGC	215;217;217	G;G;C	215;217;216	penA.9.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3882	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2953	164.1	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2242	2244	GGC	221;221;221	G,C;G;C	220,1;221;221	penA.9.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3882	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2953	164.1	1	SNP	p	L552S	0	.	.	1654	1656	CTG	2260	2262	CTG	221;220;222	C,G;T;G	219,2;220;222	penA.9.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5192	ponA	2397	2397	100.0	ponA.l6.c4.ctg.1	3473	186.4	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1781	1783	CCG	211;210;210	C;C,G;G	211;209,1;210	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2296	porA	1146	1146	99.65	porA.l15.c4.ctg.1	2484	115.5	0	.	p	.	0	M83fs	FSHIFT	247	247	A	911	911	C	188	C	188	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	544	282	porB1a	984	156	92.95	porB1a.l15.c4.ctg.3	156	52.1	0	.	p	.	0	V258L	NONSYN	772	774	GTA	15	17	TTA	31;33;33	T,G;T;A	30,1;33;33	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	544	282	porB1a	984	156	92.95	porB1a.l15.c4.ctg.3	156	52.1	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	60	62	CAT	65;65;65	C;A;T	65;65;65	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	544	282	porB1a	984	156	92.95	porB1a.l15.c4.ctg.3	156	52.1	0	.	p	.	0	D274S	NONSYN	820	822	GAT	63	65	AGT	65;65;65	A;G;T	65;65;65	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	544	282	porB1a	984	156	92.95	porB1a.l15.c4.ctg.3	156	52.1	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	72	74	TAC	65;65;65	T;A,T,C;C	65;63,1,1;65	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	544	282	porB1a	984	100	94.0	porB1a.l15.c4.ctg.4	182	44.6	0	.	p	.	0	M18T	NONSYN	52	54	ATG	133	135	ACG	47;44;43	A;C;G	47;44;43	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	544	282	porB1a	984	100	94.0	porB1a.l15.c4.ctg.4	182	44.6	0	.	p	.	0	E32Q	NONSYN	94	96	GAA	175	177	CAA	11;10;7	C;A;A	11;10;7	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2590	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1807	176.7	0	.	p	.	0	N38E	NONSYN	112	114	AAT	568	570	GAA	225;225;224	G;A;A	225;225;224	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2590	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1807	176.7	0	.	p	.	0	N134D	NONSYN	400	402	AAT	856	858	GAT	213;213;215	G;A;T,G	213;213;214,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2590	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1807	176.7	0	.	p	.	0	P175S	NONSYN	523	525	CCA	979	981	TCA	225;226;224	T;C,G;A	225;225,1;224	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2590	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1807	176.7	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1108	1110	GTC	212;211;211	G;T,G;C	212;210,1;211	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2590	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1807	176.7	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1438	1440	GCA	182;180;181	G,T;C;A	181,1;180;181	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2590	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1807	176.7	1	SNP	p	G120K	1	.	.	358	360	AAG	814	816	AAG	214;216;219	A,G;A,G,C;G,T	213,1;214,1,1;218,1	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2590	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1807	176.7	1	SNP	p	A121D	1	.	.	361	363	GAC	817	819	GAC	221;222;221	G;A,C,G;C	221;220,1,1;221	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2590	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1807	176.7	1	SNP	p	D121N	0	.	.	361	363	GAC	817	819	GAC	221;222;221	G;A,C,G;C	221;220,1,1;221	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	539	9040	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	5445	207.4	1	SNP	p	H553N	1	H553N	NONSYN	1657	1659	CAT	2256	2258	AAT	216;214;217	A;A,C;T	216;213,1;217	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1346	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1712	98.2	1	SNP	p	V57M	1	.	.	169	171	ATG	859	861	ATG	234;233;230	A;T,A;G	234;232,1;230	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
